Oral Cyclophosphamide and Etoposide in Treatment of Malignant Pleural Mesothelioma

  • Gunduz, Seyda (Department of Medical Oncology, Antalya Education and Research Hospital) ;
  • Mutlu, Hasan (Department of Medical Oncology, Akdeniz University Faculty of Medicine) ;
  • Goksu, Sema Sezgin (Department of Medical Oncology, Akdeniz University Faculty of Medicine) ;
  • Arslan, Deniz (Department of Medical Oncology, Akdeniz University Faculty of Medicine) ;
  • Tatli, Ali Murat (Department of Medical Oncology, Akdeniz University Faculty of Medicine) ;
  • Uysal, Mukremin (Department of Medical Oncology, Afyon Kocatepe University Ahmet Necdet Sezer Research and Practice Hospital) ;
  • Coskun, Hasan Senol (Department of Medical Oncology, Akdeniz University Faculty of Medicine) ;
  • Bozcuk, Hakan (Department of Medical Oncology, Akdeniz University Faculty of Medicine) ;
  • Ozdogan, Mustafa (Department of Medical Oncology, Antalya Medstar Hospital) ;
  • Savas, Burhan (Department of Medical Oncology, Akdeniz University Faculty of Medicine)
  • Published : 2014.11.06


Background: Malignant mesothelioma (MM) is almost always fatal and few treatment options are available. The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients who underwent standard treatment for advanced MM. Materials and Methods: This study included 22 malignant pleural mesothelioma patients who were treated with oral cyclophosphamide and etoposide (EE). Results: The average follow-up period of the patients was 39.1 months. Under the treatment of oral EE, median progression-free survival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR (5.8-50.3)]. The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12 (54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%). Conclusions: Oral EE can be administered effectively to patients with inoperable malignant mesothelioma who had previously received standard treatments.


  1. Bott M, Brevet M, Taylor BS, et al (2011). The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet, 43, 668-72
  2. Aisner J (1995). Current approach to malignant mesothelioma of the pleura. Chest, 107, 332.
  3. Berk S, Dogan T D, Kilickap S, et al (2012). Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years' experience in Turkey. Asian Pac J Cancer Prev, 13, 5735-9.
  4. Bianchi C, Bianchi T (2012). Malignant mesothelioma in Eastern Asia. Asian Pac J Cancer Prev, 13, 4849-53.
  5. Ceresoli GL, Zucali PA, Gianoncelli L, et al (2010). Secondline treatment for malignant pleural mesothelioma. Cancer Treat Rev, 36, 24-32.
  6. Ibrahim N1, Abou-Elela E and Darwish D (2013). Survival of mesothelioma in a palliative medical care unit in Egypt. Asian Pac J Cancer Prev, 14, 739-42.
  7. Collova E, Sebastiani F, De Matteis E, et al (2011). Use of metronomic chemotherapy in oncology: results from a national Italian survey. Tumori, 97, 454-8.
  8. Flores RM, Akhurst T, Gonen M, et al (2003). Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 126, 11-6.
  9. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-86.
  10. Janne PA (2003). Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer, 5, 98-106.
  11. Herndon JE, Green MR, Chahinian AP, et al (1998). Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia Group B. Chest, 113, 723-31.
  12. Kieran MW, Turner CD, Rubin JB, et al (2005). A feasibility trial of anti-angiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol, 27, 573-81.
  13. Kim MJ, Cui FJ, Kim Y (2013) Hydrogen peroxide promotes epithelial to mesenchymal transition and stemness in human malignant mesothelioma cells. Asian Pac J Cancer Prev, 14, 3625-30
  14. Kumar-Singh S, Vermeulen PB, Weyler J, et al (1997). Evaluation of tumor angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol, 182, 211-16.<211::AID-PATH834>3.0.CO;2-D
  15. Kumar-Singh S, Weyler J, Martin MJ, et al (1999). Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol, 189, 72-8.<72::AID-PATH401>3.0.CO;2-0
  16. Ohta Y, Shridhar V, Bright RK, et al (1999). VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumors. Br J Cancer, 81, 54-61.
  17. Kucukoner M, Isikdogan A, Yaman S, et al (2012). Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: A study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 13, 3973-6.
  18. Mutlu H, Buyukcelik A,Karaca H, et al (2013). Secondline chemotherapy versus best supportive care for malignant pleural mesothelioma. Asian Pac J Cancer Prev, 14, 3887-9.
  19. O'Byrne KJ, Edwards JG, Waller DA (2004). Clinicopathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer, 4,45-8.
  20. Ong ST, Vogelzang NJ (1996). Chemotherapy in malignant pleural mesothelioma. J Clin Oncol, 14, 1007.
  21. Plathow C, Staab A, Schmaehl A, et al (2008). Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol, 43, 737-44.
  22. Porpodis K, Zarogoulidis P, Boutsikou E, et al (2013). Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis, 5, 397-406.
  23. Stebbing J, Powles T, McPherson K, et al (2009). The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer, 63, 94-97.
  24. Tsao AS, Wistuba I, Roth JA, Kindler HL (2009). Malignant pleural mesothelioma. J Clin Oncol, 27, 2081-90.
  25. Utkan G, Urun Y, Cangir AK, et al (2013). Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: No role for ABO-Rh blood groups. Asian Pac J Cancer Prev, 14, 249-253
  26. Zucali P, Garassino I, Ceresoli G, et al (2006). Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer, 54, 48.
  27. Van Gosen BS, Blitz TA, Plumlee GS, et al (2013). Geologic occurrences of erionite in the United States: an emerging national public health concern for respiratory disease. Environ Geochem Health, 35, 419-30.
  28. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44.
  29. Yip CSP, Koong HN, Loo CM, et al (2011). Malignant pleural mesothelioma in Singapore. Asian Pac J Cancer Prev, 12, 1155-9.